Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.

A Comparative Analysis of SG&A Expenses: Genmab A/S vs Catalent, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Catalent, Inc. from 2014 to 2023. Over this period, Genmab A/S has shown a remarkable increase in SG&A expenses, growing by over 4,000% from 2014 to 2023. In contrast, Catalent, Inc. experienced a more modest growth of approximately 180% during the same timeframe. Notably, Genmab's expenses surged significantly in 2022, reaching a peak in 2023, while Catalent's expenses showed a steady upward trend. This disparity highlights Genmab's aggressive expansion and investment strategies compared to Catalent's more conservative approach. The data for 2024 is incomplete, indicating a need for further analysis as new information becomes available.